Should intravesical Bacillus Calmette–Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
2020 ◽
Vol 38
(10)
◽
pp. 795.e9-795.e17
2016 ◽
Vol 23
(10)
◽
pp. 854-860
◽